Novartis | NOVN - Debt



Novartis reported $31.27B in Debt for its fiscal quarter ending in March of 2025.


Debt Change Date
AbbVie USD 69.89B 2.74B Mar/2025
Alcon AG USD 5.25B 57M Jun/2025
Almirall EUR 341.5M 67.31M Mar/2025
Amgen USD 56.2B 1.18B Jun/2025
AstraZeneca USD 32.84B 1.19B Jun/2025
Autolus Therapeutics Ltd 253.44M 8.84M Mar/2025
Bayer EUR 39.39B 1.31B Mar/2025
Biogen USD 6.59B 296.8M Jun/2025
Bristol-Myers Squibb USD 50.93B 1.22B Jun/2025
Eli Lilly USD 39.9B 1.39B Jun/2025
Fresenius EUR 12.85B 778M Jun/2025
Fresenius Medical Care EUR 11.02B 203.55M Jun/2025
Galapagos EUR 10.86M 864K Mar/2025
Genmab DKK 148M 5M Jun/2025
Gilead Sciences USD 24.95B 6M Jun/2025
GlaxoSmithKline GBP 17.35B 1.08B Jun/2025
GRIFOLS EUR 8.82B 1.23B Jun/2025
Hikma Pharmaceutical USD 1.31B 30M Dec/2024
J&J USD 52.25B 15.62B Mar/2025
Lonza CHF 4.71B 915M Dec/2024
Merck EUR 9.4B 704M Jun/2025
Merck USD 34.84B 2.27B Mar/2025
Novartis USD 31.27B 12M Mar/2025
Novartis USD 32.64B 1.38B Jun/2025
Novo Nordisk 118.72B 61.75B Mar/2025
Orion EUR 321.2M 6M Mar/2025
Pfizer USD 60.93B 1.18B Jun/2025
Philips EUR 8.43B 857M Jun/2025
Recordati EUR 2.47B 112.82M Jun/2025
Regeneron Pharmaceuticals USD 2.71B 300K Jun/2025
Roche Holding CHF 34.44B 5.23B Jun/2024
Sanofi 22.28B 1.24B Jun/2025
UCB EUR 3.03B 12M Dec/2024